Notice2022-12655
Advisory Committee; Science Advisory Board to the National Center for Toxicological Research; Renewal
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 13, 2022
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA or Agency) is announcing the renewal of the Science Advisory Board to the National Center for Toxicological Research (NCTR) by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Science Advisory Board to the National Center for Toxicological Research for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the June 2, 2024, expiration date.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 113 (Monday, June 13, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 113 (Monday, June 13, 2022)]
[Notices]
[Pages 35787-35788]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-12655]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2022-N-0686]
Advisory Committee; Science Advisory Board to the National Center
for Toxicological Research; Renewal
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; renewal of Federal advisory committee.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the renewal of the Science Advisory Board to the National Center for
Toxicological Research (NCTR) by the Commissioner of Food and Drugs
(the Commissioner). The Commissioner has determined that it is in the
public interest to renew the Science Advisory Board to the National
Center for Toxicological Research for an additional 2 years beyond the
charter expiration date. The new charter will be in effect until the
June 2, 2024, expiration date.
DATES: Authority for the Science Advisory Board to the National Center
for Toxicological Research will expire on June 2, 2024, unless the
Commissioner formally determines that renewal is in the public
interest.
FOR FURTHER INFORMATION CONTACT: Donna L. Mendrick, National Center for
Toxicological Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 32, Rm. 2208, Silver Spring, MD 20993-0002, 301-
796-8892, <a href="/cdn-cgi/l/email-protection#783c1716161956351d161c0a111b13381e1c195610100b561f170e"><span class="__cf_email__" data-cfemail="1e5a7170707f30537b707a6c777d755e787a7f3076766d30797168">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: Pursuant to 41 CFR 102-3.65 and approval by
the Department of Health and Human Services pursuant and by the General
Services Administration, FDA is announcing the renewal of the Science
Advisory Board to the National Center for Toxicological Research (the
Committee). The Committee is a discretionary Federal advisory committee
established to provide advice to the Commissioner. The Committee
advises the Commissioner or designee in discharging responsibilities as
they relate to helping to ensure safe and effective drugs for human use
and, as required, any other product for which FDA has regulatory
responsibility.
The Committee advises the Director, NCTR, in establishing,
implementing, and evaluating research programs that assist the
Commissioner in fulfilling his regulatory responsibilities. The
Committee provides an extra-agency review in ensuring that the research
programs at NCTR are scientifically sound and pertinent.
The Committee shall consist of a core of nine voting members
including the Chair. Members and the Chair are selected by the
Commissioner or designee from among authorities knowledgeable in the
fields of toxicological research. Members will be invited to serve for
overlapping terms of up to 4 years. Almost all non-Federal members of
this committee serve as Special Government Employees. Federal members
will be appointed as Regular Government Employees or Ex-Officios. The
core of voting members may include one technically qualified member,
selected by the Commissioner or designee, who is identified with
consumer interests and is recommended by either a consortium of
consumer-oriented organizations or other interested persons.
The Commissioner or designee shall have the authority to select
members of other scientific and technical FDA advisory committees
(normally not to exceed 10 members) to serve temporarily as voting
members and to designate consultants to serve temporarily as voting
members when: (1) expertise is required that is not available among
current voting standing members of the Committee (when additional
voting members are added to the Committee to provide needed expertise,
a quorum will be based on the combined total of regular and added
members) or (2) to comprise a quorum when, because of unforeseen
circumstances, a quorum is or will be lacking. Because of the size of
the Committee and the variety in the types of issues that it will
consider, FDA may, in connection with a particular committee meeting,
specify a quorum that is less than a majority of the current voting
members. The Agency's regulations (21 CFR 14.22(d)) authorize a
committee charter to specify quorum requirements.
If functioning as a medical device panel, an additional non-voting
representative member of consumer interests will be included in
addition to the voting members.
[[Page 35788]]
Further information regarding the most recent charter and other
information can be found at <a href="https://www.fda.gov/advisory-committees/toxicological-research-science-advisory-board-national-center-toxicological-research/charter-science-advisory-board-national-center-toxicological-research">https://www.fda.gov/advisory-committees/toxicological-research-science-advisory-board-national-center-toxicological-research/charter-science-advisory-board-national-center-toxicological-research</a> or by contacting the Designated Federal Officer
(see FOR FURTHER INFORMATION CONTACT). In light of the fact that no
change has been made to the committee name or description of duties, no
amendment will be made to 21 CFR 14.100.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app.). For general information related to FDA advisory
committees, please visit us at <a href="http://www.fda.gov/AdvisoryCommittees/default.htm">http://www.fda.gov/AdvisoryCommittees/default.htm</a>.
Dated: June 3, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-12655 Filed 6-10-22; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on June 13, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.